Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium.
Best Pract Res Clin Gastroenterol. 2011 Apr;25 Suppl 1:S19-26. doi: 10.1016/S1521-6918(11)70006-3.
The important co-existence of spondylarthritis (SpA) and inflammatory bowel disease (IBD) within the same individual suggests common etiopathogenic mechanisms. This is supported by intriguing similarities between both diseases at the subclinical and molecular level. The recent advances in IBD genetics have led to the identification of common pathways involved in both IBD and SpA, including bacterial recognition and ER stress. This offers the opportunity to develop potential new therapeutic strategies for both diseases. Transgenic animals which develop both joint and gut inflammation (like the TNF(ΔARE) mice and the HLA-B27 transgenic rats) are a very useful tool to test such novel therapeutics and to get further mechanistic insight into the pathogenetic link between SpA and IBD. This review will focus on the recent scientific progress in our understanding of the link between SpA and IBD. Based on this, potential novel therapeutic strategies are discussed.
强直性脊柱炎（SpA）和炎症性肠病（IBD）在同一患者中重要共存提示存在共同的发病机制。这一观点得到了疾病在亚临床和分子水平上的有趣相似性的支持。IBD 遗传学的最新进展导致了在 IBD 和 SpA 中涉及的共同途径的鉴定，包括细菌识别和内质网应激。这为两种疾病提供了开发潜在新治疗策略的机会。同时发展关节和肠道炎症的转基因动物（如 TNF(ΔARE)小鼠和 HLA-B27 转基因大鼠）是一种非常有用的工具，可用于测试此类新型治疗药物，并深入了解 SpA 和 IBD 之间的发病机制联系。这篇综述将重点介绍我们对 SpA 和 IBD 之间联系的理解的最新科学进展。在此基础上，讨论了潜在的新型治疗策略。
